Jessica Tait

MONASH UNIVERSITY

Australia

Research Interests

Explore related searches

Professors in Australia

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (12)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Collaborators (11)

Jürgen Bulitta

Professor and Perry E. Foote Eminent Scholar Chair

University of Florida

UNITED STATES

View details

Kevin Batty

Professor & Director of Pharmacy

Curtin University

AUSTRALIA

View details

Timothy Barnett

University of Western Australia

AUSTRALIA

View details

Ben Boyd

Københavns Universitet

DENMARK

View details

Steven Wallis

Head of Bioanalysis

University of Queensland

AUSTRALIA

View details

Jonathan Carapetis

University of Western Australia

AUSTRALIA

View details

Darren J Creek

MONASH UNIVERSITY

AUSTRALIA

View details

Yinzhi Lang

Research Asst. Professor

University of Florida

UNITED STATES

View details

John Boyce

MONASH UNIVERSITY

AUSTRALIA

View details

Laurens Manning

University of Western Australia

AUSTRALIA

View details

Sam Salman

University of Western Australia

AUSTRALIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jessica Tait

Research Interests

Explore related searches

Contact this professor

Articles (12)

Multiomics informed mathematical model for meropenem and tobramycin against hypermutable Pseudomonas aeruginosa

Cholesterol-terminated cationic lipidated oligomers (CLOs) as a new class of antifungals

Providing insight into the mechanism of action of cationic lipidated oligomers using metabolomics

Identifying and mathematically modeling the time-course of extracellular metabolic markers associated with resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa

Development of a sustained release implant of benzathine penicillin G for secondary prophylaxis of rheumatic heart disease

Ceftolozane-Tazobactam against Pseudomonas aeruginosa Cystic Fibrosis Clinical Isolates in the Hollow-Fiber Infection Model: Challenges Imposed by Hypermutability and Heteroresistance

Effect of Different Piperacillin-Tazobactam Dosage Regimens on Synergy of the Combination with Tobramycin against Pseudomonas aeruginosa for the Pharmacokinetics of Critically Ill Patients in a Dynamic Infection Model

Simulated Intravenous versus Inhaled Tobramycin with or without Intravenous Ceftazidime Evaluated against Hypermutable Pseudomonas aeruginosa via a Dynamic Biofilm Model and Mechanism-Based Modeling

Penicillin G concentrations required for prophylaxis against Group A Streptococcus infection evaluated using a hollow fibre model and mathematical modelling

Pharmacodynamics of ceftazidime plus tobramycin combination dosage regimens against hypermutable Pseudomonas aeruginosa isolates at simulated epithelial lining fluid concentrations in a dynamic in vitro infection model

Evaluation of Meropenem-Ciprofloxacin Combination Dosage Regimens for the Pharmacokinetics of Critically Ill Patients With Augmented Renal Clearance.

Clinically Relevant Epithelial Lining Fluid Concentrations of Meropenem with Ciprofloxacin Provide Synergistic Killing and Resistance Suppression of Hypermutable Pseudomonas aeruginosa in a Dynamic Biofilm Model.

Collaborators (11)

Jürgen Bulitta

Kevin Batty

Timothy Barnett

Ben Boyd

Steven Wallis

Jonathan Carapetis

Darren J Creek

Yinzhi Lang

John Boyce

Laurens Manning

Sam Salman

Make your next move.